​

Verrica Pharmaceuticals (VRCA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

VRCA Stock Forecast

Verrica Pharmaceuticals (VRCA) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $17.00, with a high of $17.00 and a low of $17.00. This represents a 171.57% increase from the last price of $6.26.

- $4 $8 $12 $16 $20 High: $17 Avg: $17 Low: $17 Last Closed Price: $6.26

VRCA Stock Rating

Verrica Pharmaceuticals stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (60.00%), 4 Hold (40.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 4 6 Strong Sell Sell Hold Buy Strong Buy

VRCA Price Target Upside V Benchmarks

TypeNameUpside
StockVerrica Pharmaceuticals171.57%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$17.00$17.00
Last Closing Price$6.26$6.26$6.26
Upside/Downside-171.57%171.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Mar, 26-41--5
Feb, 26-41--5
Jan, 26-41--5
Dec, 25-32--5
Nov, 25-22--4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 18, 2025Kemp DolliverLoop Capital Markets$17.00$8.05111.18%171.57%
May 14, 2024Glen SantangeloJefferies$12.00$11.286.38%91.69%
May 14, 2024Oren LivnatH.C. Wainwright$14.00$9.5646.44%123.64%
Jul 25, 2023Serge BelangerNeedham$10.00$5.3287.97%59.74%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 07, 2026Cowen & Co.BuyBuyhold
Oct 21, 2024Cowen & Co.BuyBuyhold
Oct 02, 2024NeedhamBuyHolddowngrade
May 14, 2024JefferiesBuyBuyhold
May 14, 2024H.C. WainwrightBuyBuyhold
Jul 25, 2023NeedhamBuyupgrade
Feb 13, 2023RBC CapitalSector PerformOutperformupgrade
May 25, 2022RBC CapitalSector Performdowngrade

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-12.97$-7.17$-14.78$-14.78$-1.68---
Avg Forecast$-1.46$-0.91$-1.39$-1.45$-0.60$-0.37$-0.13$-0.01
High Forecast$-0.99$-0.71$-1.34$-1.34$-0.24$-0.10$0.17-
Low Forecast$-1.87$-1.25$-1.44$-1.55$-0.79$-0.66$-0.62$-0.01
Surprise %788.36%687.91%963.31%919.31%180.00%---

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$12.00M$9.03M$5.12M$7.57M$35.58M---
Avg Forecast$12.00M$7.42M$4.03M$8.25M$14.34M$32.60M$65.81M$101.80M
High Forecast$14.60M$9.53M$4.33M$9.44M$14.68M$44.27M$89.36M$138.24M
Low Forecast$9.06M$6.15M$3.87M$7.07M$14.01M$22.30M$45.02M$69.64M
Surprise %-21.80%27.29%-8.34%148.02%---

Net Income Forecast

$-85M $-66M $-47M $-28M $-9M $10M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-35.08M$-24.49M$-67.00M$-76.58M$-17.89M---
Avg Forecast$-65.97M$-41.45M$-63.07M$-65.34M$-23.53M$-17.19M$846.33K$-226.71K
High Forecast$-44.98M$-32.26M$-60.85M$-60.63M$-11.03M$-4.67M$7.64M$-133.60K
Low Forecast$-84.58M$-56.82M$-65.28M$-70.06M$-36.03M$-29.71M$-28.13M$-332.19K
Surprise %-46.83%-40.93%6.23%17.20%-23.98%---

VRCA Forecast FAQ

Is Verrica Pharmaceuticals stock a buy?

Verrica Pharmaceuticals stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 4 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Verrica Pharmaceuticals is a favorable investment for most analysts.

What is Verrica Pharmaceuticals's price target?

Verrica Pharmaceuticals's price target, set by 10 Wall Street analysts, averages $17 over the next 12 months. The price target range spans from $17 at the low end to $17 at the high end, suggesting a potential 171.57% change from the previous closing price of $6.26.

How does Verrica Pharmaceuticals stock forecast compare to its benchmarks?

Verrica Pharmaceuticals's stock forecast shows a 171.57% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Verrica Pharmaceuticals over the past three months?

  • March 2026: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2026: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • January 2026: 0% Strong Buy, 80.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.

What is Verrica Pharmaceuticals’s EPS forecast?

Verrica Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.37, marking a -77.98% decrease from the reported $-1.68 in 2025. Estimates for the following years are $-0.13 in 2027, and $-0.01 in 2028.

What is Verrica Pharmaceuticals’s revenue forecast?

Verrica Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $32.6M, reflecting a -8.37% decrease from the reported $35.58M in 2025. The forecast for 2027 is $65.81M, and $101.8M for 2028.

What is Verrica Pharmaceuticals’s net income forecast?

Verrica Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-17.187M, representing a -3.91% decrease from the reported $-17.886M in 2025. Projections indicate $846.33K in 2027, and $-227K in 2028.